Skye Bioscience (SKYE)
NASDAQ:SKYE
SKYE Stock Chart & Stats
$0.72
-$0.06(-1.95%)
At close: 4:00 PM EST
$0.72
-$0.06(-1.95%)
Day’s Range― - ―
52-Week Range$0.57 - $5.75
Previous CloseN/A
Volume18.00K
Average Volume (3M)810.33K
Market Cap
$24.03M
Enterprise Value$18.52M
Total Cash (Recent Filing)$25.74M
Total Debt (Recent Filing)$273.65K
Price to Earnings (P/E)―
Beta2.63
Next Earnings
May 07, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding33,378,765
10 Day Avg. Volume167,219
30 Day Avg. Volume810,330
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.48
Price to Sales (P/S)0.00
P/FCF Ratio-0.69
Enterprise Value/Market Cap0.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-102.89
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$9.16Price Target Upside1172.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Durability Of Weight LossLonger-term clinical data indicate nimacimab added to GLP-1 therapy substantially reduces weight regain and sustains greater weight loss compared with GLP-1 therapy alone, supporting its role as a durability-enhancing adjunct.
Regulatory Clarity And Trial DesignRegulatory guidance established an add-on trial framework with semaglutide and a defined efficacy benchmark, reducing design uncertainty for planned later-stage studies.
Safety And Dose OptimizationClean safety results with no serious adverse events create a wide therapeutic window that enables testing higher nimacimab doses to potentially improve efficacy.
Bears Say
Data Robustness And ComparabilitySmall sample sizes, potential selection bias in control groups and loss of randomization complicate comparisons across study arms and indicate larger randomized trials are needed to validate the observed effects.
Efficacy Uncertainty Due To Study FocusPart C is primarily a pharmacokinetic and safety dose-selection study rather than a definitive efficacy readout, leaving uncertainty about nimacimab's standalone clinical effectiveness.
Translational Risk From Preclinical DataPreclinical dose-response and mechanistic signals may not reproduce in humans, and absence of confirmed biomarkers increases uncertainty that higher doses will deliver the expected durability benefits.
Skye Bioscience News
SKYE FAQ
What was Skye Bioscience’s price range in the past 12 months?
Skye Bioscience lowest stock price was $0.56 and its highest was $5.75 in the past 12 months.
What is Skye Bioscience’s market cap?
Skye Bioscience’s market cap is $24.03M.
When is Skye Bioscience’s upcoming earnings report date?
Skye Bioscience’s upcoming earnings report date is May 07, 2026 which is in 22 days.
How were Skye Bioscience’s earnings last quarter?
Skye Bioscience released its earnings results on Mar 10, 2026. The company reported -$0.36 earnings per share for the quarter, missing the consensus estimate of -$0.297 by -$0.063.
Is Skye Bioscience overvalued?
According to Wall Street analysts Skye Bioscience’s price is currently Undervalued.
Does Skye Bioscience pay dividends?
Skye Bioscience does not currently pay dividends.
What is Skye Bioscience’s EPS estimate?
Skye Bioscience’s EPS estimate is -0.31.
How many shares outstanding does Skye Bioscience have?
Skye Bioscience has 33,378,765 shares outstanding.
What happened to Skye Bioscience’s price movement after its last earnings report?
Skye Bioscience reported an EPS of -$0.36 in its last earnings report, missing expectations of -$0.297. Following the earnings report the stock price went down -9.649%.
Which hedge fund is a major shareholder of Skye Bioscience?
Currently, no hedge funds are holding shares in SKYE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Skye Bioscience
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.
SKYE Company Deck
SKYE Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with strong financial health and promising Phase 2a study results highlighting the potential of Nimazumab in combination with semaglutide. However, increased R&D expenses, a larger net loss, concerns about monotherapy efficacy, and limited study enrollment were notable challenges.View all SKYE earnings summariesSKYE Stock 12 Month Forecast
Average Price Target
$9.16
▲(1172.22% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
Outlook Therapeutics
―
Bioxcel Therapeutics
―
Inmune Bio
―
Lantern Pharma
―
Ownership Overview
Currently, No data available
---